Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 899 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of the Cervix Clear all

Conditions: Cervical Cancer
Interventions: Demographic Form and Semi-Structured Interview Guide; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions: Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography; Other · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: capecitabine, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Interventions: Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 541
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more

Conditions: Uterine Cervical Neoplasms
Interventions: E7 T-Cell Receptor (TCR); Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Papilloma Virus
Interventions: Zinc Sulfate, Placebo (Gelatin Tablet); Dietary Supplement · Other
Lead sponsor: Corewell Health West; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Cervical Cancer Screening
Interventions: wPap Mobile Web App Intervention; Behavioral
Lead sponsor: University of South Dakota; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lake Andes, South Dakota

Conditions: Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions: Echopulse, Poly ICLC, Standard of Care PD-1 Therapy; Device · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cervical Cancer
Interventions: human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer Screening
Interventions: Evalyn Self-Sampling Brush; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Lung Cancer, Nonsmall Cell, Melanoma (Skin)
Interventions: Tumor Profiling; Diagnostic Test
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Precancerous Condition
Interventions: Usual care mailing intervention, CIS support mailing intervention; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
Interventions: Nintedanib, Bevacizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Fenretinide, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Intraepithelial Neoplasia
Interventions: E7 TCR; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions: ²¹²Pb-DOTAM-GRPR1; Drug
Lead sponsor: Orano Med Theranostics, SAS; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions: fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy; Radiation · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 24
States / cities: Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more

Conditions: Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions: SGN-STNV; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more

Conditions: Cervical Cancer
Interventions: recombinant interleukin-12; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 9
States / cities: Boston, Massachusetts • Flemington, New Jersey • Hackensack, New Jersey + 6 more

Conditions: Cervical Cancer
Interventions: M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Atlanta, Georgia • Lafayette, Louisiana + 12 more

Conditions: Cervical Cancer, Genital Warts
Interventions: Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late; Biological
Lead sponsor: Duke University; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Uterine Cervical Neoplasms
Interventions: [F18]Fluorothymidine; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Atypical Endometrial Hyperplasia, Human Papillomavirus Infection, Stage 0 Cervical Cancer AJCC v7
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 135
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 100 more

Search by objective public record fields.

Vietnamese Women's Health Project III

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer

Zinc Sulfate for Human Papillomavirus (HPV)

A Mobile Web App Intervention to Promote Cervical Cancer Screening

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

St. Joe's Invitation Effectiveness Study

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Activating Collaborative CIS Support Via Targeted Provider Mailing

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Fenretinide in Treating Patients With Cervical Neoplasia

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

A Study of SGN-STNV in Advanced Solid Tumors

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

FLT PET Imaging for Cervical Cancer

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells